Clinical Trials Browser

OTHER × Gefitinib × Clear all

NCT00238628 2026-06-04

A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer

Phase 1/2 Completed

Lung Neoplasms

NCT03122717 2026-04-29

Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT07477457 2026-03-17

A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma

Phase 2 Recruiting

Neoplasm Metastasis, Osteosarcoma

NCT07458919 2026-03-09

Therapy for Advanced NSCLC With EGFR 19delins Mutation

Phase EARLY_PHASE1 Not yet recruiting

Lung Neoplasms

NCT06675695 2026-01-30

Emulation of the FLAURA (NCT02296125) Trial Using Specialty Oncology Electronic Health Records Databases

Carcinoma, Non-Small-Cell Lung

NCT03292133 2025-06-10

A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer

Phase 2 Terminated

11 enrolled 10 charts

Lung Neoplasms

NCT00328562 2025-05-04

ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung Cancer

Phase 1 Completed

13 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT06071013 2025-01-23

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06592989 2025-01-10

A Clinical Study of Sorafenib Combined With Gefitinib for the Treatment of pNET

Adenoma, Islet Cell

NCT02347839 2024-12-10

NEGOTIATE

Phase 2 Withdrawn

Lung Neoplasms

NCT04322890 2024-10-22

PIKACHU

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT01513174 2024-06-28

GOAL

Phase 1/2 Completed

186 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung

NCT00198380 2024-03-08

Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature

Phase 2 Completed

Adenocarcinoma, Bronchiolo-Alveolar

NCT01185158 2023-11-29

A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma

Phase 2 Completed

Lymphoid Interstitial Pneumonia, Head and Neck Neoplasms, Laryngeal Diseases

NCT00483561 2023-09-13

Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy

Phase 2 Terminated

26 enrolled 7 charts

Prostatic Neoplasms

NCT04642547 2023-08-01

Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma

Phase NA Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT01833572 2023-07-12

Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT01185171 2023-05-11

Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer

Phase 2 Completed

70 enrolled 11 charts

Lymphoid Interstitial Pneumonia, Head and Neck Neoplasms, Laryngeal Diseases

NCT01570296 2023-03-29

BKM120

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT02447419 2022-06-15

Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid Tumors

Phase 2 Completed

Other solid neoplasm

Solid Tumor

NCT03170180 2022-06-15

Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer

Phase 2 Completed

Gastrointestinal

Stomach Neoplasms

NCT01951469 2022-03-08

Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer

Phase 3 Unknown

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT03239015 2022-03-04

Efficacy and Safety of Precision Therapy in Refractory Tumor

Phase 2 Unknown

Neoplasms

NCT00317772 2022-02-07

Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer

Phase 1/2 Completed

19 enrolled 12 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT02804776 2021-06-02

PROGRESS

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT02025218 2021-04-01

IRENE

Phase 2 Terminated

Lung Neoplasms

NCT02893332 2021-02-03

Sindas

Phase 3 Terminated

Stage IV EGFR Mutated Non-Small Cell Lung Cancer

NCT01556191 2021-01-08

LADIE

Phase 2 Completed

Lung Neoplasms

NCT04575415 2020-10-20

BELLA

NSCLC

NCT04115410 2020-05-28

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

Carcinoma, Non-Small-Cell Lung

NCT04358562 2020-04-24

Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT01405079 2020-02-18

ADJUVANT

Phase 3 Unknown

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01933347 2020-02-06

Third-line Treatment of Gefitinib in NSCLC Patients

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT02745691 2019-12-13

Psychometric Properties of the EORTC QLQ-LC29

Lung Neoplasms

NCT04028778 2019-11-08

FL-ALTER

Phase 3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT00014183 2019-11-07

ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney Cancer

Phase 2 Completed

Carcinoma, Renal Cell, Kidney Neoplasms

NCT04007835 2019-07-05

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

Phase NA Unknown

NSCLC

NCT00282100 2019-04-16

Adjuvant Therapy of Gefitinib (Iressa, ZD1839) in Patients With Resectable Hepatocellular Carcinoma

Phase 2 Unknown

Gastrointestinal

Liver Neoplasms

NCT02889692 2019-04-11

Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma

Phase 3 Completed

Lung Neoplasms, Neoplasms

NCT02929693 2019-04-11

Clinical Study of YYJD Decoction Combined With Gefitinib in Advanced Pulmonary Adenocarcinoma

Phase 3 Unknown

Neoplasms

NCT02142036 2019-03-13

MetAction

Phase 2 Completed

Neoplasm Metastasis

NCT03766490 2019-01-30

Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer

Phase NA Unknown

Non-Small-Cell Lung

NCT00493025 2018-12-06

Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery

Phase 2 Terminated

19 enrolled 4 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT03656393 2018-09-04

RCTACSCNSCLC

Phase 3 Unknown

NSCLC

NCT03602027 2018-07-26

Phase I Study of the Combination of Anlotinib With Gefitinib

Phase NA Unknown

Non-squamous Non-small Cell Lung Cancer

NCT00027625 2018-06-27

Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma

Phase 1 Completed

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

NCT00025675 2018-06-26

Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors

Phase 2 Completed

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Meningioma, Oligodendroglioma, Central Nervous System Neoplasms, Glioma, Subependymal, Gliosarcoma

NCT01864681 2018-06-20

CGMT

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT00215202 2018-05-17

Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)

Phase 2 Completed

Adrenal Cortex Neoplasms, Adrenal Gland Neoplasms

NCT02836847 2018-05-07

Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

Phase 2 Unknown

Gastrointestinal

Gallbladder Neoplasms